CONTROL BIONICS LIMITED — Investor Presentation 2024

Apr 22, 2024

==> picture [255 x 85] intentionally omitted <==

Next-generation assistive technology and data measurement

I N V E S T O R P R E S E N T A T I O N A P R I L 2 0 2 4

==> picture [555 x 518] intentionally omitted <==

C O N T R O L B I O N I C S . C O M | A S X : C B L

==> picture [1440 x 80] intentionally omitted <==

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Control Bionics Limited (Control Bionics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Control Bionics at the date of the presentation material, neither Control Bionics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied upon as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for the own investment purposes. Any and all use of the information is at your own risk.

No representations, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by and person (including Control Bionics). In particular, no representation ,warranty or assurance (express or implied) is given in relation to any underlying assumptions or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Control Bionics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations to any forward looking statements or any change in events, conditions or circumstances on which and such statement is based. Nothing in these materials shall under any circumstances create an implication that there has be been no change in the affairs of the Group since the date of these materials.

I N T R O D U C T I O N

Proven core technology now with infinite possibilities

We are empowering communication and enhancing lives with a vision to revolutionise medicine, sports science, rehabilitation and more with our nextgeneration EMG technology

==> picture [1440 x 80] intentionally omitted <==

I N T R O D U C T I O N

On the cusp of rapid global growth

A proven medical device company with sizeable global sales of core products that we design and manufacture

==> picture [69 x 68] intentionally omitted <==

==> picture [69 x 67] intentionally omitted <==

==> picture [78 x 78] intentionally omitted <==

20 years of Core business Regulatory expertise with our clearance and continues to grow world-first, best-inpatent protected organically in class proprietary in US, AU, UK, Australia, the US technology Japan and Europe and Japan

Blue sky and diversification opportunities with next generation solutions

Many levers for Near cash flow growth with new breakeven* products, uses, excluding sales markets, and from new channel partners initiatives

before corporate overheads

==> picture [1440 x 80] intentionally omitted <==

I N T R O D U C T I O N

EMG technology is at the heart of our solutions

==> picture [126 x 145] intentionally omitted <==

==> picture [125 x 34] intentionally omitted <==

==> picture [74 x 111] intentionally omitted <==

==> picture [125 x 34] intentionally omitted <==

An EMG signal is detected.

==> picture [157 x 81] intentionally omitted <==

==> picture [125 x 82] intentionally omitted <==

Our patented code creates a “switch” to operate devices

==> picture [236 x 197] intentionally omitted <==

Your brain sends a thought like “move my index finger”.

To move your finger, an electrical signal is created and

Electromyography (EMG) is the detection of this signal.

Our core IP uses smart

algorithms to detect, analyse and convert your body’s bioelectrical EMG into code so a user can select an item and operate a device.

Users can type, generate speech, send emails, browse the web, stream entertainment, access social apps, control their environment (lights, electric beds), play with toys, and more.

==> picture [82 x 82] intentionally omitted <==

EMG CAPTURES, RECORDS AND INTERPRETS ELECTRICAL ACTIVITY PRODUCED IN YOUR BODY’S MUSCLES WHEN YOU MOVE

==> picture [1440 x 80] intentionally omitted <==

I N T R O D U C T I O N

The evolution of our core IP

Smaller, wireless and wearable

==> picture [148 x 13] intentionally omitted <==

----- Start of picture text -----

NEUROEDUCATOR
----- End of picture text -----

==> picture [231 x 231] intentionally omitted <==

One of the first prototype systems in the NeuroEDUCATOR series was developed 20 years ago with feedback from Stephen Hawking who trialled our technology for many years.

==> picture [132 x 31] intentionally omitted <==

==> picture [103 x 13] intentionally omitted <==

----- Start of picture text -----

NEUROSTRIP
----- End of picture text -----

==> picture [226 x 225] intentionally omitted <==

==> picture [225 x 225] intentionally omitted <==

==> picture [125 x 33] intentionally omitted <==

==> picture [125 x 33] intentionally omitted <==

==> picture [382 x 134] intentionally omitted <==

----- Start of picture text -----

Just launched in 2023, the NeuroStrip
weighs less than a piece of paper and
is a miniature version of our core IP.
It’s our main lever for growth with
unlimited uses beyond disability.
----- End of picture text -----

A wireless, wearable NeuroNode was first launched in 2017. Using our IP, EMG assists disabled people in accessing technology for the world’s best communication experience.

==> picture [112 x 37] intentionally omitted <==

Solutions

Assistive Mobility

==> picture [263 x 264] intentionally omitted <==

Assistive Communication Data Measurement

==> picture [1440 x 80] intentionally omitted <==

P R O D U C T O V E R V I E W

Core products and those newly launched Currently assisting those disabled and leaping to new untapped markets

CUSTOMERS

CURRENT CORE PRODUCTS

NEW PRODUCTS

Disabled and diseased people with degenerative neurological conditions, spinal cord injuries, ASSISTIVE cerebral palsy, and other COMMUNICATIONS conditions with movement restrictions.

Speech-generating solutions with flexible access methods (touch, eye, EMG) to assist people with various conditions. NeuroNode bundles give the world’s easiest and fastest communication experience with the least effort.

==> picture [106 x 49] intentionally omitted <==

==> picture [80 x 39] intentionally omitted <==

==> picture [106 x 37] intentionally omitted <==

==> picture [86 x 37] intentionally omitted <==

==> picture [69 x 40] intentionally omitted <==

Standalone EMG and spatial access method that can connect to competitor products for the best available communication experience.

==> picture [128 x 30] intentionally omitted <==

Disabled and diseased people who have powered wheelchairs. This population size is ASSISTIVE larger than the assistive MOBILITY communication market.

A world-first allowing powered wheelchair users to safely and independently navigate their home.

==> picture [116 x 35] intentionally omitted <==

Endless market and application possibilities outside of the disability market like medicine, DATA sports science and MEASUREMENT rehabilitation.

A world-first all-in-one accelerometer and EMG device that measures physiological data like unintentional muscle movement.

NEUROSTRIP

==> picture [1440 x 80] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

3 types of technology access Flexible access to communication and speech-generating technology for those who cannot speak

==> picture [50 x 49] intentionally omitted <==

==> picture [57 x 32] intentionally omitted <==

TOUCH ACCESS

For those who can touch a computer screen to select letters, words, phrases, or symbols to learn language or communicate.

EYE ACCESS

EyeGaze is our state-of-the-art eye tracking system enabling those who can only move their eyes to control a computer mouse. The highly accurate camera with learning algorithm and software determines what button the user is looking at and, if they hold their gaze long enough, the device selects it. For both in and outdoor use.

connects

Our key communication device and software

==> picture [216 x 165] intentionally omitted <==

==> picture [62 x 64] intentionally omitted <==

EMG AND SPATIAL ACCESS

Only possible with our patented NeuroNode. It’s a wireless, noninvasive EMG and spatial sensor that communicates with a display device via Bluetooth, acting as a bridge between a person’s thoughts and technology. This is the world’s fastest access method.

A computer to generate speech, browse the web, listen to music, and more. Other devices like smartphones, Xbox, robotics, and electric beds can also be connected to our system.

==> picture [1440 x 80] intentionally omitted <==

==> picture [677 x 605] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

==> picture [249 x 58] intentionally omitted <==

Our core IP remains innovative and without major competition even today

Those with degenerative neurological conditions, spinal cord injuries, cerebral palsy, and other conditions with movement restrictions can now access a computer, phone, tablet, and . other assistive devices with subtle muscle signals

On the communication device, NeuroNode acts as a switch that is translated into a mouse click to manipulate the client’s communication and control software.

There is also a provisional patent for our AI-based software that gamifies our core technology . This means our users can create original content like digital art and stories to share with teachers, parents and loved ones. We believe this is also a world first.

Watch to see NeuroNode in action

==> picture [1440 x 80] intentionally omitted <==

==> picture [627 x 581] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

==> picture [239 x 109] intentionally omitted <==

Our flagship product is the world’s fastest, lowestfatigue eye-tracking system , combining a camera, computer and NeuroNode (EMG/spatial) control

This 3 in 1 solution suits those living with paralysis and loss of speech. Unlike other technologies, no movement is required to communicate.

Studies show typing is much faster with our 47% Trilogy product bundle than just using other standalone eye tracking technology

==> picture [202 x 169] intentionally omitted <==

==> picture [1440 x 80] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N P R O D U C T S U I T E

A voice for those without

Bundle with a NeuroNode for faster, less tiring and easier communication

==> picture [388 x 160] intentionally omitted <==

USER TYPES A user’s condition will determine the type of access method and hence product PRICING ($AUD FOR AUSTRALIAN USERS) Rental with buyout option starting price Buyout option starting price SPEECH GENERATING COMPUTER & SOFTWARE Powerful, professional-grade system including language software for use on the go

==> picture [47 x 47] intentionally omitted <==

==> picture [47 x 172] intentionally omitted <==

EYE TRACKING TECHNOLOGY

Controls a computer mouse with your eyes using a camera and continuous learning algorithm NEURONODE SENSOR

==> picture [56 x 59] intentionally omitted <==

EMG signal and spatial control gives users flexibility to change access modes

==> picture [93 x 46] intentionally omitted <==

==> picture [115 x 41] intentionally omitted <==

==> picture [140 x 111] intentionally omitted <==

==> picture [125 x 96] intentionally omitted <==

==> picture [165 x 111] intentionally omitted <==

==> picture [155 x 111] intentionally omitted <==

==> picture [69 x 83] intentionally omitted <==

==> picture [55 x 55] intentionally omitted <==

Entry level access for Entry level for those who A UnoTouch upgrade Includes all 3 access types those who can touch a can only move their eyes with EMG access for for ultimate efficiency or screen to communicate to communicate greater efficiency high physical incapacity $1,000 $3,800 $5,400 $8,000 n/a $3,200 $9,000 $16,875 $20,875 $950 Access smart phones, play video games, activate switch toys, dine independently, and more

==> picture [1440 x 80] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

Why our communication solutions are better

Other Providers	Control Bionics	Benefit to the customer
Require a keyboard, mouse, joystick, touchscreen, or eye tracking to function.	Uses EMG and/or eye tracking.	Proven to be both faster and less fatiguing in multiple studies. It also reduces repetitive strain injuries and gives people who cannot use eye technologies, like those with cerebral palsy, the ability to communicate.
Require movement.	Can detect the intention of movement whilst excluding unintentional movement -	Less fatigue, faster, and more consistent communication. Can be used by severely disabled people who cannot move at all.
	patent protected.
Single solution offering (eg Tobii or Smart Box).	Offers a choice of speech- generating software, cameras and casings.	Allows customers to make a choice based on the best-suited system for their needs, ensuring effective use and reduced device abandonment.
Only wired or Bluetooth or EMG	Only company to combine spatial, EMG and EOG switch.	Allows flexibility and versatility of use. Caters to a user’s changing needs during the day and as their condition changes over time.

Proven to be both faster and less fatiguing in multiple studies. It also reduces repetitive strain injuries and gives people who cannot use eye technologies, like those with cerebral palsy, the ability to communicate. Less fatigue, faster, and more consistent communication. Can be used by severely disabled people who cannot move at all. Allows customers to make a choice based on the best-suited system for their needs, ensuring effective use and reduced device abandonment. Allows flexibility and versatility of use. Caters to a user’s changing needs during the day and as their condition changes over time. Our patent-protected settings ensure a user’s intentions are acted on rather than any unintentional movements.

==> picture [1440 x 80] intentionally omitted <==

A S S I S T I V E M O B I L I T Y

Independent, safe travel within the home

==> picture [421 x 109] intentionally omitted <==

A new world first autonomous wheelchair

==> picture [149 x 100] intentionally omitted <==

Watch Me

Partnering with Deakin University, we made the world’s first upgrade for powered wheelchairs, so the user’s intentions can control them

DROVE is a patent pending module that retrofits powered wheelchairs. Its technology helped us rank 4th in AFR’s Australia’s Most Innovative Healthcare Companies 2023.

TGA registration expected FY24.

First sales are expected in the coming months as we build towards 3rd party distribution relationships.

In Jan-24, we were awarded a A$575k research grant by the US ALS Association to assess how DROVE could be sold in the US. International interest is also growing.

==> picture [1440 x 80] intentionally omitted <==

==> picture [462 x 215] intentionally omitted <==

B E Y O N D A S S I S T I V E T E C H N O L O G Y

The new NeuroStrip is a game-changer

A lightweight, flexible design means the NeuroStrip can be worn anywhere on the body.

We are on a path to revolutionise new markets such as health diagnostics, sports science, critical care and more with the new miniaturisation of our world-class, awardwinning core technology

The NeuroStrip measures physiological data as an all-in-one unique accelerometer and EMG device. This means it opens up endless market and . application possibilities beyond disability

The electrode is attached directly to the skin, detecting the faintest of signals, with best-in-class data telemetry fed straight to an app.

Our strategy is to enter markets with the quickest, lowest-cost access requiring no further approvals. Currently, these are likely to be sports performance, biofeedback, and rehabilitation.

Partner for those applications needing more research or clinical trials. Low-cost and high-volume product relative to our other products.

==> picture [1440 x 80] intentionally omitted <==

B E Y O N D A S S I S T I V E T E C H N O L O G Y

NeuroStrip features and benefits

F E A T U R E

B E N E F I T

==> picture [119 x 46] intentionally omitted <==

==> picture [106 x 20] intentionally omitted <==

----- Start of picture text -----

NeuroStrip
----- End of picture text -----

Small, light, flexible and non-invasive. At 3g, it weighs less than a piece of paper and is 4cm long.

Increased choice of placement where you want to switch with, monitor or improve. It’s also easy to use.

==> picture [59 x 46] intentionally omitted <==

==> picture [114 x 225] intentionally omitted <==

----- Start of picture text -----

real-time
data
streaming
----- End of picture text -----

Better uses for medicine, sports science, rehabilitation and other applications yet to be discovered. Increases the number of applications across markets.

With no cables or moving parts, it has unprecedented accuracy (<1 micro volt) with more sensitive readings. Attaches directly to the skin with no limit to how many are used at any one time.

Measures a wide range of electrical Flexibility in choice of signal and signals in the body like EOG, ECG, EMG ability to measure both intended and (and potentially unintended movement for a wider electroencephalography EEG). range of outcomes. Disposable (reusable in final development). Can be used in medical settings

==> picture [1440 x 80] intentionally omitted <==

P R O D U C T

Regulatory approvals

	US	Australia	Japan	UK	Europe
Regulatory Scheme	FDA	TGA	PMDA	MHRA	CE Mark
NeuroNode
DROVE
**NeuroStrip ***
May require further approvals if the product use materially changes
Approved
Pending or near-term application
Yet to be approved

==> picture [112 x 37] intentionally omitted <==

Assistive Technology Market

Communication

Mobility

==> picture [1440 x 80] intentionally omitted <==

Our users

Our devices help people of all ages living with conditions like ALS/Motor Neuron Disease (MND), Spinal Muscular Atrophy, Cerebral Palsy, and Spinal Cord Injury to control communication technology

US AND AUSTRALIAN SALES BY CONDITION

Amyotrophic Lateral Sclerosis (ALS) 25%

==> picture [317 x 278] intentionally omitted <==

----- Start of picture text -----

Cerebral Palsy (CP)
25%
----- End of picture text -----

==> picture [34 x 25] intentionally omitted <==

----- Start of picture text -----

Other
50%
----- End of picture text -----

Other neurodegenerative diseases, brain injury, stroke, genetic etc

==> picture [585 x 363] intentionally omitted <==

“Since starting to work with this EMG technology, I have been able to connect technology with people who have some of the greatest communication challenges I have ever seen in my 25-year career.

I have been able to help people who could not speak, move, eat, or breathe on their own, and communicate to loved ones, even when they were placed into ICU units or in palliative care”

-Speech Language Pathologist (SLP)

==> picture [1440 x 80] intentionally omitted <==

Minimum $1.3bn global market opportunity p.a.

An underserved niche market with few competitors and plenty of room for growth in the US, UK, Japan, Australia and select European countries

About 66,000 new cases are diagnosed each year for ALS/Motor Neuron Disease, Multiple Sclerosis, Cerebral Palsy and Spinal Cord Injuries in our chosen markets. This represents a $1.3bn+ market opportunity per annum.

However, the market is significantly larger at $2bn+ as we can now offer our products to people with existing assistive communication technology. By upgrading to our NeuroNode, customers get a faster, easier and more consistent communication experience.

==> picture [656 x 352] intentionally omitted <==

----- Start of picture text -----

First sales in Japan
in 2023 for our
Well established
newly launched
sales in US and
strategy to offer
monthly breakeven
NeuroNode as a
expected Dec-24
standalone device.
Dominant Australian market
share that is at break even
----- End of picture text -----

Existing sales for our bundled offerings eg NeuroNode Trilogy.

New markets for standalone NeuroNode - Japan, UK, Germany, Belgium, and the Netherlands given regulatory approvals in March 2024 for the UK and Europe. NZ will also be considered.

==> picture [1440 x 80] intentionally omitted <==

Minimum $100 million market opportunity p.a.

This is a new market for us where our add-on module to powered wheelchairs allows users to independently and safely navigate their homes

The market opportunity is based on a 1% penetration of new global annual sales.

The opportunity may be 4x larger as millions of powered wheelchairs currently exist around the world that could also use DROVE.

==> picture [234 x 70] intentionally omitted <==

==> picture [228 x 229] intentionally omitted <==

----- Start of picture text -----

2 million
Powered
wheelchairs sold
globally each year
----- End of picture text -----

==> picture [419 x 271] intentionally omitted <==

==> picture [391 x 206] intentionally omitted <==

New markets where DROVE is expected to be sold.

==> picture [112 x 37] intentionally omitted <==

Current Business Model

A retail business model where our sales team work with prescribers to offer just assistive communication solutions.

==> picture [1440 x 80] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

The market’s most personalised solution

OUR PRESCRIBERS

Prescribers demonstrate and recommend our solutions. They include Speech Language Pathologists (SLPs), industry bodies, clinics, schools, hospitals and more

==> picture [185 x 33] intentionally omitted <==

==> picture [55 x 55] intentionally omitted <==

==> picture [55 x 55] intentionally omitted <==

==> picture [55 x 55] intentionally omitted <==

==> picture [55 x 55] intentionally omitted <==

==> picture [55 x 55] intentionally omitted <==

LANGUAGE SYSTEM

Our catalogue of synthetic voices, library of symbols, and text-based systems are customised solutions for both younger and older users.

SOFTWARE

Our software allows users to access their devices, text, browse the web, control robotics, play video games, access social apps, develop literacy skills, create their own artwork and more.

HARDWARE

Our hardware options are chosen to suit the customer and include a computer, various eye tracking cameras and NeuroNode (bundled with other hardware or standalone). Our Cosmos Connect device connects our system to smartphones, gaming consoles, accessible toys, robotics, electric beds, lights and more.

FUNDING

Our funding team helps families and professionals apply for funding through Government and private insurance.

SUPPORT

We provide education and hands-on training through professionals so our customers get the most out of their personalised solutions.

==> picture [108 x 11] intentionally omitted <==

----- Start of picture text -----

OUR SOLUTION
----- End of picture text -----

==> picture [528 x 371] intentionally omitted <==

----- Start of picture text -----

LANGUAGE SYSTEM
SUPPORT 24/7
SOFTWARE
USERS
FUNDING HARDWARE
Solutions with a NeuroNode
give us a competitive advantage
----- End of picture text -----

==> picture [1440 x 80] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

Funding overview

==> picture [1282 x 394] intentionally omitted <==

----- Start of picture text -----

At least 75% of our sales are
Other
other
8%
through a person’s insurer 13%
Federal
35%
Medicare /
3rd Party Billing
Medicaid /
29% Veteran Affairs /
STAPP (Texas)
USA
AUSTRALIA
Private Insurance
NDIS National Disability
Private pay
12% Insurance Scheme
87%
16%
----- End of picture text -----*

‘* Outsource to third-party biller who collects from the insurer (both public and private) Data based on FY24 YTD

==> picture [112 x 37] intentionally omitted <==

Growth Strategy A new wholesale business model where we work with resellers and partners to offer more products with more uses in more geographical locations, generating new income streams and recurring revenue.

==> picture [337 x 277] intentionally omitted <==

==> picture [1440 x 80] intentionally omitted <==

G R O W T H S T R A T E G Y

New wholesale strategy for growth

Continued innovation means we can further diversify the use of our products and enter new markets

==> picture [397 x 277] intentionally omitted <==

----- Start of picture text -----

OUR SOLUTIONS
SOFTWARE HARDWARE SUPPORT 24/7
NEUROSTRIP
----- End of picture text -----

NEURONODE ADVANTAGE

DROVE ADVANTAGE

World first product with compelling benefits to users, family and care givers

Quicker to market

Can be used with competitor products as an add-on upgrade Gives distributors an edge because they can now offer an EMG switch that no one else has

Priced to be attractive to both insurers, private pay and government funders

Can be quickly installed, maintains the relationship between distributor and client

Enhances new sales

Price control

DROVE distributor package provides both software and hardware

Lower fixed cost base Profitable more quickly Higher volume sales

==> picture [103 x 31] intentionally omitted <==

----- Start of picture text -----

RESELLER OR
PARTNER
----- End of picture text -----

==> picture [41 x 13] intentionally omitted <==

----- Start of picture text -----

USER
----- End of picture text -----

==> picture [48 x 52] intentionally omitted <==

==> picture [58 x 50] intentionally omitted <==

NEUROSTRIP ADVANTAGE

Flexibility and versatility of use creates for multiple distribution routes

Securing data collected behind the walled garden of the NS app ensures CBL sits in the centre

Reusable and disposable options allows for a wide range of uses

Lower cost EMG device will drive demand in new product markets

==> picture [1440 x 80] intentionally omitted <==

G R O W T H S T R A T E G Y

Multiple levers for growth

==> picture [55 x 51] intentionally omitted <==

==> picture [49 x 49] intentionally omitted <==

==> picture [52 x 46] intentionally omitted <==

==> picture [41 x 49] intentionally omitted <==

CURRENT SALES STATUS

NEW GEOGRAPHIES

NEW CHANNEL PARTNERS

NEW USE TYPE

==> picture [141 x 33] intentionally omitted <==

==> picture [125 x 38] intentionally omitted <==

NEUROSTRIP

Japan was the first market Our next focus is the UK and for our new NeuroNode select continental European wholesale strategy in 2023 countries for disabilities, including and our first sales were a significant cerebral palsy market captured in 1H24. of some 400,000 people.

Japan was the first market Our next focus is the UK and Currently building distributor No - assistive for our new NeuroNode select continental European partnerships where our technology market wholesale strategy in 2023 countries for disabilities, including strong patent portfolio and only. and our first sales were a significant cerebral palsy market lack of competition give us captured in 1H24. of some 400,000 people. the best market opportunity. First sales expected in The recent ALS grant will help us Currently building distributor No - assistive coming months in Australia. research the best entry paths into partnerships with powered technology market the US. wheelchair manufacturers. only. The first batch of Our initial focus is to leverage our We have commenced Yes (see over) commercial-grade market position in our existing discussions in the US, Australia NeuroStrips was recently markets of Australia, US and Japan and Japan for potential manufactured. for sales. partnerships for NeuroStrip distribution.

==> picture [1440 x 80] intentionally omitted <==

==> picture [53 x 114] intentionally omitted <==

G R O W T H S T R A T E G Y

Blue sky growth strategy with NeuroStrip

REGULATORY REQUIREMENTS None

EASE OF MARKET ENTRY SELLING POINTS REGULATORY USE TYPE FOR WHAT OUTCOME / PRODUCT READINESS REQUIREMENTS Sports science sEMG is used to assess muscle CBL has existing track record Lightweight, wireless, None performance and recovery and customers in this space. electrode against the with the objective of making This is our likely launch skin to improve data. the sportsperson more market. effective and reducing injury. Rehab and Assess: level and timing of Will require development of Lightweight, wireless, Minimal. NeuroEDUCATOR biofeedback muscle activation, muscle marketing materials and testing available for in clinic (a pre-cursor to NS) already fatigue, provide uptraining and of user interface to meet market and at home use. has FDA approval as Class I device. Will submit an down- training of muscles. demand. engineering change notice to Device ready to go. Some further benefit from that approval work may be required on App. extending to the NS Movement sEMG is used to diagnose and Can commence customer trials Lightweight, wireless, Will require Class II registration disorders treat conditions such as quickly. However, likely to require electrode against the if being used to diagnose Parkinson's and Myasthenia some regulatory approvals to skin to improve data treatment. As sEMG already gravis. PKG operates in this scale. used for this condition there is market but does not use sEMG. an understandable / App was designed with this use manageable process to receive case. this clearance.

Will require Class II registration if being used to diagnose treatment. As sEMG already used for this condition there is an understandable / manageable process to receive this clearance.

CURRENT BUSINESS DEVELOPMENT OPPORTUNITIES

In discussions with existing customers about upgrading to NS.

Identifying sports clinics (US) that currently use sEMG in their service.

In discussions with existing customers about upgrading to NS. Have multiple partnership opportunities in Japan. Discussions underway in Australia about clinical deployment.

Have identified minimum viable product (MVP) with world-leading doctors. With commercial quantities now available, will move to discuss clinical implementation with them.

==> picture [1440 x 80] intentionally omitted <==

==> picture [53 x 114] intentionally omitted <==

G R O W T H S T R A T E G Y

Blue sky growth strategy with NeuroStrip

FOR WHAT OUTCOME

USE TYPE

sEMG biofeedback is used to Dysphagia retrain people on swallowing.

An example here

EASE OF MARKET ENTRY / PRODUCT READINESS

Established market however new to CBL.

Required to develop a specific front end for users.

SELLING POINTS Lightweight, wireless, available for in clinic and at home use.

REGULATORY REQUIREMENTS

Minimal. NeuroEDUCATOR (a pre-cursor to NS) already has FDA approval as Class I device. Will submit an engineering change notice to benefit from that approval extending to the NS.

CURRENT BUSINESS DEVELOPMENT OPPORTUNITIES

CBL previously approached by Dysphagia clinics to use our technology. Will now reengage.

Incontinence sEMG could be used to manage incontinence through the placement of the NS over the bladder muscles.

Significant opportunity but would likely require clinical and industry partners to scale. Would require ‘productisation’.

Lightweight, wireless, flexible electrode against the skin. Ability to provide haptic feedback and create alerts for user and care staff.

Will require Class II registration.Higher level of approvals as sEMG being used for a unique purpose.

Initial discussions with a globally recognised Uroneurologist.

Obvious market demand and efficacy of sEMG use in incontinence management are already established.

==> picture [1440 x 80] intentionally omitted <==

G R O W T H S T R A T E G Y

Roadmap

Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25
DROVE TGA approval	First sales DROVE expected	US breakeven expected	Final tranche of US	FDA submission for DROVE
			research grant payment
NeuroStrip customer trials start	New partnerships for standalone NeuroNode	Japan breakeven expected	for DROVE
	strategy in Japan and Europe
NeuroStrip App v1.0 release	Prototype for first	First EU sales for NeuroNode expected
	reuseable NeuroStrip
NeuroStrip launch at AI For Good conference in Geneva	finalised Clinical trials commence in	First NeuroStrip research partner
	the US for DROVE
	First commercial sales of
	NeuroStrip in sports and
	rehab segments

==> picture [112 x 37] intentionally omitted <==

Financial Performance

==> picture [1440 x 80] intentionally omitted <==

==> picture [721 x 729] intentionally omitted <==

----- Start of picture text -----

R E V E N U E ( A $ m )
E B I T D A ( $ A m )
6 25% 0
5 -1
-2
4
-3
3
-4
2
-5
1
-6
0
2021 2022 2023
2021 2022 2023
E M P L O Y E E S % S A L E S
Australia
20%
US
Australia
Japan
US
80%
0 5 10 15 20 25
----- End of picture text -----

F I N A N C I A L S

Gaining traction year on year

300 systems sold in our key markets in FY23.

FY23 revenue up an impressive 25% over FY22.

US is the strongest market as the strength of our team and time in-market delivers.

Strong cost control saw losses narrow.

Australian operations deliver positive EBITDA for FY23. US operations are expected to be monthly breakeven by Dec-24.

Board revitalisation with new board member, Professor Rob Heard and CEO appointment of Jeremy Steele.

==> picture [1440 x 80] intentionally omitted <==

==> picture [519 x 633] intentionally omitted <==

----- Start of picture text -----

3.5
3.0
2.5
2.0
R E V E N U E ( A $ m )
1.5
1.0
0.5
0.0
H1 FY21 H1 FY22 H1 FY23 H1 FY24
0.0
-0.5
-1.0
E B I T D A ( $ A m ) -1.5
-2.0
-2.5
-3.0
H1 FY21 H1 FY22 H1 FY23 H1 FY24
----- End of picture text -----

F I N A N C I A L S

FY24 1H results

Total Revenues of $3.5m for the period. This compares to H1 2023 as follows:

Continued reduction in losses in EBITDA over the same comparative period in 2023 ($1.8m from $2.5m).

The US represented 80% of the revenue.

30% reduction in cash used in operating activities.

First revenues were reported in Japan with the unbundled version of the NeuroNode product.

Significant delays in NDIS approvals impacted the Australian business. A substantial backlog of approvals exists, materially larger than at any other time in the business’ history.

Focused on the production of NeuroStrip for release into the market and TGA Assessment of our new DROVE product.

==> picture [112 x 37] intentionally omitted <==

Company

==> picture [1440 x 80] intentionally omitted <==

P E O P L E

Experienced leadership

B O A R D

==> picture [174 x 118] intentionally omitted <==

==> picture [117 x 116] intentionally omitted <==

==> picture [163 x 109] intentionally omitted <==

Peter Ford

Jeremy Steele Managing Director CEO

Roger Hawke

Chairman Independent Non Executive Director

Founder & Non Executive Director Brett Crowley Company Secretary

==> picture [175 x 116] intentionally omitted <==

==> picture [115 x 114] intentionally omitted <==

Prof Rob Heard

Damian Lismore Independent Non Executive Director

Independent Non Executive Director

==> picture [592 x 680] intentionally omitted <==

==> picture [1440 x 80] intentionally omitted <==

Corporate Summary

T O P S H A R E H O L D E R S

F I N A N C I A L I N F O R M A T I O N

Phoenix Development 18.32% Nightingale Partners 12.47% Peter Shann Ford 11.50% Top 20 hold 73.1% of shares

Share price (19/4/24) A$0.044 Shares on issue 170.7 million Market capitalisation A$7.51 million Cash (31/03/24) A$0.88 million Unlisted options / performance rights 4.37 million Debt Nil

G e t i n t o u c h

C O M P A N Y

I N V E S T O R R E L A T I O N S

==> picture [145 x 145] intentionally omitted <==

==> picture [145 x 145] intentionally omitted <==

J O E D U R A K E X E C U T I V E D I R E C T O R & F O U N D E R L Y N X A D V I S O R S

J E R E M Y S T E E L E C E O C O N T R O L B I O N I C S

j s t e e l e @ c o n t r o l b i o n i c s . c o m + 6 1 4 3 3 2 2 9 4 7 0

j o e @ l y n x a d v i s o r s . c o m . a u + 6 1 4 1 4 4 6 5 5 8 2

C O N T R O L B I O N I C S . C O M | A S X : C B L

==> picture [371 x 635] intentionally omitted <==

==> picture [112 x 37] intentionally omitted <==

Additional Information

==> picture [1440 x 80] intentionally omitted <==

B E Y O N D A S S I S T I V E T E C H N O L O G Y

NeuroStrip helps elite athletes jump higher and reduce injury

==> picture [197 x 38] intentionally omitted <==

N E U R O B O U N C E U S E S O U R T E C H N O L O G Y

A professional sports scientist currently uses our EMG technology to train the brain of his athletes so the motor neuron recruitment to muscles used in jumping can be maximised. With specially designed strength and power training, this results in greater explosiveness, power, and vertical jump height.

Every muscle used in jumping consists of thousands of individual muscle fibres, which must receive signals from the brain to be activated during athletic performance. A higher percentage of fibres in a given muscle that is activated (and then strengthened and trained correctly) results in more power, explosiveness, and vertical jump ability. This will give an athlete an extremely competitive edge in any sport.

Electrodes are placed on the upper and lower quads and calves to recruit and strengthen the muscle fibres.

==> picture [532 x 564] intentionally omitted <==

==> picture [1440 x 80] intentionally omitted <==

A B O U T

Our technology is 20 years in the making

==> picture [190 x 49] intentionally omitted <==

“Peter Ford, the founder, was inspired by Stephen Hawking and how there had to be a better way to help people like Stephen Hawking participate more in society.

Peter trialled the concept with Stephen Hawking over a period of five years.

His input helped shape our journey and where we are today” Former CEO Rob Wong

$20.79m NeuroNode Registration with UK Medical Neurostrip Regulator Roger Hawke Jeremy Steele (miniaturised joins as chairman joins as CEO core IP) launches 2020 - MAR 2024 Control First batches of Bionics IPO Neurostrip manufactured DROVE module for Autonomous powered wheelchairs Wheelchair Project - launches US Research Award